Movement Alert｜Philip Morris Rises 4.02% in Regular Trading, Q2 Revenue Beats Expectations as ZYN Expansion Accelerates

Market Focus

Jul 22

On July 22, Philip Morris rose 4.02% in regular trading, trading at $197.245/share, with turnover of $99.33 million. The move was driven by a strong Q2 revenue beat and continued momentum in the company's ZYN nicotine pouch business.

Philip Morris reported Q2 revenue growth of 10.4% to $11.19 billion, significantly exceeding the analyst consensus of $10.63 billion. The company is accelerating investment in its ZYN brand in the US, having launched Zyn Ultra in June — a higher-strength wet nicotine pouch variant priced below its flagship Zyn product to defend market share amid intensifying competition. Additional dry-format variants in 1.5mg and 8mg strengths are planned for Q3.

Separately, the US FDA issued Modified Risk Tobacco Product orders for 20 ZYN products in early July, authorizing the company to market health-related claims comparing ZYN favorably to cigarettes. However, Philip Morris cut its full-year adjusted EPS guidance to $8.11–$8.26, below the FactSet estimate of $8.36, citing competitive pressures and unfavorable currency movements, marking its third downward revision this year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1153184077"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153184077\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153184077?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 21:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153184077","market":"us","top_or_hot":-1,"title":"Movement Alert｜Philip Morris Rises 4.02% in Regular Trading, Q2 Revenue Beats Expectations as ZYN Expansion Accelerates","media":"Market Focus","content":"<p><p>On July 22, Philip Morris rose 4.02% in regular trading, trading at $197.245/share, with turnover of $99.33 million. The move was driven by a strong Q2 revenue beat and continued momentum in the company's ZYN nicotine pouch business.</p><p>Philip Morris reported Q2 revenue growth of 10.4% to $11.19 billion, significantly exceeding the analyst consensus of $10.63 billion. The company is accelerating investment in its ZYN brand in the US, having launched Zyn Ultra in June — a higher-strength wet nicotine pouch variant priced below its flagship Zyn product to defend market share amid intensifying competition. Additional dry-format variants in 1.5mg and 8mg strengths are planned for Q3.</p><p>Separately, the US FDA issued Modified Risk Tobacco Product orders for 20 ZYN products in early July, authorizing the company to market health-related claims comparing ZYN favorably to cigarettes. However, Philip Morris cut its full-year adjusted EPS guidance to $8.11–$8.26, below the FactSet estimate of $8.36, citing competitive pressures and unfavorable currency movements, marking its third downward revision this year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Philip Morris Rises 4.02% in Regular Trading, Q2 Revenue Beats Expectations as ZYN Expansion Accelerates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Philip Morris Rises 4.02% in Regular Trading, Q2 Revenue Beats Expectations as ZYN Expansion Accelerates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-22 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 22, Philip Morris rose 4.02% in regular trading, trading at $197.245/share, with turnover of $99.33 million. The move was driven by a strong Q2 revenue beat and continued momentum in the company's ZYN nicotine pouch business.</p><p>Philip Morris reported Q2 revenue growth of 10.4% to $11.19 billion, significantly exceeding the analyst consensus of $10.63 billion. The company is accelerating investment in its ZYN brand in the US, having launched Zyn Ultra in June — a higher-strength wet nicotine pouch variant priced below its flagship Zyn product to defend market share amid intensifying competition. Additional dry-format variants in 1.5mg and 8mg strengths are planned for Q3.</p><p>Separately, the US FDA issued Modified Risk Tobacco Product orders for 20 ZYN products in early July, authorizing the company to market health-related claims comparing ZYN favorably to cigarettes. However, Philip Morris cut its full-year adjusted EPS guidance to $8.11–$8.26, below the FactSet estimate of $8.36, citing competitive pressures and unfavorable currency movements, marking its third downward revision this year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PM","symbol_name":"菲利普莫里斯","start_time":0,"source_url":"","article_id":"1153184077","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153184077","pubTimestamp":1784727614,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 22, Philip Morris rose 4.02% in regular trading, trading at $197.245/share, with turnover of $99.33 million. The move was driven by a strong Q2 revenue beat and continued momentum in the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PM":"菲利普莫里斯"},"translate_title":"走势提醒|菲利普莫里斯常规交易上涨 4.02%，ZYN 扩张加速，第二季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PM":1},"content_text":"On July 22, Philip Morris rose 4.02% in regular trading, trading at $197.245/share, with turnover of $99.33 million. The move was driven by a strong Q2 revenue beat and continued momentum in the company's ZYN nicotine pouch business.Philip Morris reported Q2 revenue growth of 10.4% to $11.19 billion, significantly exceeding the analyst consensus of $10.63 billion. The company is accelerating investment in its ZYN brand in the US, having launched Zyn Ultra in June — a higher-strength wet nicotine pouch variant priced below its flagship Zyn product to defend market share amid intensifying competition. Additional dry-format variants in 1.5mg and 8mg strengths are planned for Q3.Separately, the US FDA issued Modified Risk Tobacco Product orders for 20 ZYN products in early July, authorizing the company to market health-related claims comparing ZYN favorably to cigarettes. However, Philip Morris cut its full-year adjusted EPS guidance to $8.11–$8.26, below the FactSet estimate of $8.36, citing competitive pressures and unfavorable currency movements, marking its third downward revision this year.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}